Oprettet 04/06/2014 – 15:59
Janssen-Cilag announced today that the European Commission has approved the use of SYLVANT® for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are HIV negative and HHV-8 negative. SYLVANT® is the firts medicine to recieve regolatory approval in the EU for the treatment of MCD patients.